Pharmacokinetics of Glycyrrhetic Acid, a Major Metabolite of Glycyrrhizin, in Rats

Shiro Ishida, a,1 Yoko Sakita, a Tsutomu Ichikawa, a and Shoji Awazu,b

Faculty of Pharmaceutical Sciences, Tokushima Bunri University,a Yamashiro-cho, Tokushima 770, Japan and Department of Biopharmaceutics, Tokyo College of Pharmacy,b 1432-1 Horinouchi, Hachioji, Tokyo 192-03, Japan. Received May 1, 1989

The pharmacokinetics of glycyrrhetic acid (GLA) was examined in rats after bolus i.v. injection at a dose of 2.5, or 12 mg/kg. The decline in plasma concentration was generally biexponential at each dose, but the terminal disposition became much slower with increase of dose. A greater than proportional increase in plasma GLA concentration was observed with increase of dose, suggesting a dose-dependency of GLA disposition. Apparent total body clearance decreased significantly with increase of dose. On the other hand, the apparent steady-state distribution volume after i.v. administration was unaffected by dose. The plasma disposition at each dose fitted well to a two-compartment pharmacokinetic model with Michaelis–Menten elimination. It was concluded that the pharmacokinetics of GLA in the rat is dose-dependent owing to a saturable elimination rate. The plasma level of GLA after glycyrrhizin (GLZ) i.v. dosing (100 mg/kg) in the control rats (without biliary fistulization) sustained the concentration range of 1.5–3 μg/ml during 1–48 h, but that in the rats with biliary fistulization declined with time. It was suggested that the sustained plasma level of GLA is accounted for by the intestinal reabsorption of GLA produced from GLZ and GLA-conjugates during the enterohepatic recycling of both.

Keywords glycyrrhetic acid; pharmacokinetics; dose-dependency; saturable elimination; tissue distribution

Glycyrrhetic acid (GLA), the aglycone of glycyrrhizin (GLZ), has many therapeutic effects, e.g., anti-ulcer,1 anti-inflammatory,2-4 anti-hepatotoxic,5-7 interferon-inducing,8,9 and anti-tumor10 actions. GLA has been used in the treatment of Addison’s disease,11 essential hypotension,12 and neurodermatitis.13 However, GLA has been reported to produce the adverse effect of aldosteroneism owing to its aldosterone-like effect,14 potentiating effect on the action of aldosterone,15 and inhibiting effect on aldosterone metabolism.16 GLA is produced from GLZ by hydrolysis after administration of GLZ to humans,17 rats,18 rabbits,19 rats,20 and rabbits.21 GLZ has frequently been used in the treatment of chronic hepatitis22 and allergies,23 but it also exhibits pseudo-aldosteroneism.24 Oketani et al.19 reported that GLA is effective against chronic hepatitis, because only GLA is detected in human serum when GLZ is orally administered. It is desirable, therefore, to elucidate the pharmacokinetic behavior of GLA in the body in order to use it and GLZ safely in clinical therapeutics. We previously reported the biliary excretion and enterohepatic cycling of GLZ in rats.25 However, no data on the pharmacokinetic characteristics of GLA have been reported so far.

In the present study, we examined the pharmacokinetics of GLA in rats by means of measurements of the plasma disposition after a bolus 2.5, or 12 mg/kg i.v. dose and determined the tissue-to-plasma partition coefficients (Kp) at a steady-state plasma concentration. The plasma disposition of GLA after a 100 mg/kg i.v. dose of GLZ in rats was also examined.

Experimental

Materials Sodium glycyrrhetinate (GLA-Na) and GLZ were kindly supplied by Minophagen Pharmaceutical Co. (Tokyo, Japan). All other reagents were commercial products of analytical grade.

Animals Male Wistar rats (weighing 240–260 g) that had been fasted for 20 to 24 h prior to the experiments were used. Under light ether anesthesia, the right femoral artery was cannulated with PE-50 polyethylene tubing to collect blood samples in rats with and without biliary fistulization. A bile fistula was cannulated with PE-10 polyethylene tubing. The cannulated rats were kept in restraining cages with free access to water under normal housing conditions prior to the experiments. The rats were allowed to recover from anesthesia prior to the injection of the drug (approximately 1 h). For Kp determination, the right femoral vein and thoracic duct were cannulated with PE-10 polyethylene tubing to infuse GLA and to collect lymph, respectively. The body temperature was kept at 37 °C throughout the experiments by using a heat lamp.

Plasma Disposition GLA or GLZ was dissolved in 5% glucose solution. GLA (2, 5, or 12 mg/kg) and GLZ (100 mg/kg) (~1.0 ml each) were injected into the left femoral vein of the control rats (without biliary fistulization) and the control and bile duct-cannulated rats, respectively. After a bolus injection of 2 mg/kg GLA, blood samples (0.3 ml each) were collected from the canula in heparinized polyethylene centrifuge tubes at 1, 3, 5, 10, 15, 20, and 30 min. In the cases of 5 and 12 mg/kg, blood samples were taken at 1, 5, 10, 20, 30, and 60 min. In the latter case, further samples were taken at 90 and 120 min. After a bolus injection of 100 mg/kg GLZ, blood samples (0.5 ml each) were collected at 0.5, 1, 3, 5, 7, 9, 12, 20, 24, 28, 32, 36, 44, and 48 h. Rats after GLZ dosing were given fresh blood (2.0 ml), obtained from other rats, through the right femoral artery canulla immediately after each sampling at 5, 20, and 36 h. Plasma was separated by centrifugation for 5 min, and stored at −20 °C until analysis.

Determination of Plasma-to-Blood Concentration Ratio (Cp/Cb) Fresh blood was collected via the carotid artery at 40 min after an i.v. injection of heparin. After incubation of the blood sample (1.0 ml) for 5 min at 37 °C, 0.02 ml of solution containing 0.7–100 μg of GLA-Na in 5% glucose was added and the mixture was incubated for 30 min at 37 °C. Aliquots (0.3 ml) of the sample solution were centrifuged for 5 min to obtain plasma.

Determination of Tissue-to-Plasma Partition Coefficient (Kp) at a Steady-State Plasma Level (Cp0) After a loading dose of 5 mg/kg GLA, the drug was infused through the canulla at the rate of 0.224 mg/kg/min for 60 min with a constant-rate infusion pump (model KN-201, Natsume Seisakusho Co., Ltd., Tokyo, Japan). The Cp0 (ca. 55 μg/ml) was maintained within 20 min after the beginning of the infusion. Lymph was collected from 30 min to 60 min after the initiation of infusion through the thoracic duct canulla. Thereafter, a blood sample was immediately collected, then the rats were exsanguinated via a carotid artery, and perfused in situ with cold physiological saline via the venous trunk just inferior to the spinal chord and portal vein until the effusate become colorless. The brain, lung, heart, liver, stomach, small intestine, kidney, muscle, skin, spleen, pancreas, and adipose tissue were quickly excised, rinsed well with cold physiological saline, blotted, and weighed. All the samples were stored at −20 °C until required. All wet tissues were assumed to have a density of 1.0. Each tissue sample was homogenized with two volumes of physiological saline in an ice bath before analysis.

Sample Analysis Samples of 0.1 ml of blood, plasma, and lymph, and 0.3–0.6 ml of homogenate were used for the GLA determination. For the determination of GLA and GLZ after GLZ dosing, samples of 0.2 ml of plasma were used. The methods of determination of both GLA26 and GLZ were the same as those described previously, i.e., the drugs were determined by HPLC after extraction with MeOH.

Data Analysis The area under the plasma concentration time curve

© 1989 Pharmaceutical Society of Japan
(AUC) and the mean residence time (MRT) were calculated by trapezoidal integration with extrapolation to infinite time.\(^1\) The steady-state distribution volume (Vdss) and the total body clearance (CLint) were calculated from the dose MRT/AUC and dose/AUC, respectively. The plasma concentration data were fitted to differential mass balance equations for a one-, two-, or three-compartment pharmacokinetic model with Michaelis-Menten elimination from the central compartment (Fig. 1). The differential mass balance equations for each model are expressed as follows:

\[
\begin{align*}
\frac{dC_1}{dt} &= -(k_{12} + V_{max}/(K_m + C_i))C_1 + k_{21}C_1 + k_{21}C_2 \\
\frac{dC_2}{dt} &= k_{12}C_1 - k_{21}C_1 - k_{21}C_2 \\
\frac{dC_3}{dt} &= k_{13}C_1 - k_{31}C_1 - k_{31}C_3 \\
\end{align*}
\]

(Fig. 1A)

\[
\begin{align*}
\frac{dC_1}{dt} &= -(k_{12} + V_{max}/(K_m + C_i))C_1 + k_{12}C_2 + k_{21}C_2 + k_{21}C_3 \\
\frac{dC_2}{dt} &= k_{12}C_1 - k_{21}C_1 - k_{21}C_2 - k_{21}C_3 \\
\end{align*}
\]

(Fig. 1B)

\[
\begin{align*}
\frac{dC_1}{dt} &= -(k_{12} + k_{13} + V_{max}/(K_m + C_i))C_1 + k_{12}C_2 + k_{12}C_3 \\
\frac{dC_2}{dt} &= k_{12}C_1 - k_{21}C_1 - k_{21}C_2 - k_{21}C_3 \\
\end{align*}
\]

(Fig. 1C)

The initial conditions are as follows:

\[
C_i(0) = D/V_i, \quad C_2(0) = 0, \quad C_3(0) = 0
\]

where \(C_i\) is GLA concentration in the central compartment, \(C_2\) and \(C_3\) are GLA concentrations in the peripheral compartments, \(k_{12}\) and \(k_{13}\) are the first-order partition rate constants out of the central compartment, and \(k_{21}\) and \(k_{31}\) are the first-order partition rate constants back into the central compartment. \(V_i\) is the volume of distribution of the central compartment. \(V_{max}\) and \(K_m\) are the maximum velocity and the Michaelis constant, respectively. \(D\) is the amount of the dose. The fitting was performed by using the Multi-Runge program.\(^2\) Data were weighted with the reciprocals of the plasma concentrations. The apparent \(K_p\) value of liver was corrected according to Eq. 1 by the method of Chen and Gross.\(^2\)

\[
K_p = \left(\frac{Q_H + CL_{int,H}J_p}{Q_H}\right)\frac{C_H}{C_m}
\]

(1)

where \(Q_H\), \(CL_{int,H}\), \(J_p\), represent the plasma flow rate, metabolic intrinsic clearance, GLA concentration, and plasma unbound fraction, respectively, and \(H\) denotes the liver. \(Q_H\) (8.5 ml/min) was taken from the literature.\(^3\) The term \(CL_{int,H}/J_p\) was calculated by using Eq. 2.

\[
CL_{int} = \frac{Q_H + CL_{int,H}J_p}{Q_H + CL_{int,H}J_p + CL_{int,H}J_p}
\]

(2)

where \(CL_{int}\) is total body clearance at \(C_m\), which is the value obtained by dividing the constant infusion rate by \(C_m\). Statistical analysis (e.g., Student's \(t\) test with \(p = 0.05\) as the minimal level of significance).

**Results**

**Plasma Disposition** The plasma disposition of GLA after 2, 5, or 12 mg/kg i.v. administration in rats is plotted in Fig. 2. The decline in plasma concentration was generally biexponential at each dose, but the terminal disposition became much slower with increase of the dose. As shown in Table 1, a greater than proportional increase in AUC with increase of the dose was observed. This suggests dose-dependency of GLA disposition. Therefore, \(CL_{int}\) and \(V_{dss}\) were represented as apparent values (Table 1). The MRT and apparent \(CL_{int}\) values increased and decreased significantly with increase of the dose, respectively (\(p < 0.05\)). On the other hand, the apparent \(V_{ds}\) value was unaffected by dose. The plasma data at each dose were fitted to a one-, two-, or three-compartment pharmacokinetic model with
Michaels–Menten elimination from the central compartment (Fig. 1). The two-compartment model (Fig. 1B) showed the best fit to the plasma concentration data (Fig. 2). The AIC value was also smaller for the two-compartment model than for the other models (the AIC values were 78.7, 32.9, and 110.2 in the one-, two-, and three-compartment models, respectively). The pharmacokinetic parameters for the best-fit two-compartment model are listed in Table II.

Thus, it was found that GLA disposition is dose-dependent owing to saturable elimination.

**Plasma Disposition of GLA Following GLZ i.v. Dosing.** The plasma concentrations of GLA and GLZ after 100 mg/kg i.v. administration of GLZ in rats with and without biliary fistulation are plotted in Fig. 3. As reported, 20–23 GLA produced from GLZ was observed in plasma. In the control rats, the high plasma level of GLA at 1 h declined gradually with decrease of GLZ plasma level until 9 h. Thereafter, the GLA level tended to increase until 24 h, and the high level at 24 h was sustained in the concentration range of 1.5–3.0 μg/ml until the last sampling time, 48 h (Fig. 3A). In the bile duct-cannulated rats, the GLA level tended to decrease with decrease of GLZ plasma level and was no longer detectable (the limit of detection is 0.125 μg/ml). 29) after 28 h (Fig. 3B). The overall concentration of GLA in both groups was lower than 4 μg/ml.

**Plasma-to-Blood Concentration Ratio (Cp/B) As shown in Fig. 4, the Cp/B values were almost constant (1.787 ± 0.019, n = 12) over the range of plasma concentrations (2–150 μg/ml) studied. The hematocrit value was 0.454 in this study. This indicates that GLA is not well taken up into erythrocytes.

**Tissue-to-Plasma Partition Coefficient (Kp) at Steady-State Plasma Level (Cp).** The Kp values and tissue distribution volumes (Kp, Vr) are listed in Table III. All the Kp values were less than 1.0, indicating poor tissue distribution of GLA. The sum of the total tissue distribution volume (ΣKp, Vr) and plasma volume 23) is 25.424 ml/250 g, which corresponds well to the apparent Vd∞ value at 2.5, or 12 mg/kg dose (Table I). This suggests a little distribution to

---

**Table II. Pharmacokinetic Parameters of GLA Estimated Based on the Two-Compartment Model with Michaelis–Menten Elimination in Rats**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>k12 (min⁻¹)</td>
<td>0.0797 ± 0.0113</td>
</tr>
<tr>
<td>k12 (min⁻¹)</td>
<td>0.0817 ± 0.0113</td>
</tr>
<tr>
<td>Km (μg/ml)</td>
<td>27.971 ± 5.704</td>
</tr>
<tr>
<td>Vmin (μg/ml/min/kg)</td>
<td>15.329 ± 1.751</td>
</tr>
<tr>
<td>Vi (ml/kg)</td>
<td>72.293 ± 2.539</td>
</tr>
</tbody>
</table>

For details of the calculation of parameters (± computer-calculated S.D.), see the text.

---

**Fig. 3. Plasma Concentrations of GLA (●) and GLZ (○) after 100 mg/kg i.v. Administration of GLZ in Rats**

A. the control rats (without biliary fistulation); B. the bile duct-cannulated rats. Each point represents the mean ± S.E. of four to eight rats.

---

**Fig. 4. Plasma-to-Blood Concentration Ratios (Cp/B) of GLA in Rats Determined in Vitro at 37°C**

The points represent the experimental values. The line shows the mean value (1.787).

---

**Table III. Tissue-to-Plasma Partition Coefficients (Kp) and Tissue Distribution Volume (Kp, Vr) at Steady-State Plasma Concentration (Cp) of GLA in Rats**

<table>
<thead>
<tr>
<th>Tissue</th>
<th>Kp (a)</th>
<th>Vr (ml)</th>
<th>Vr (b)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brain</td>
<td>0.019 ± 0.003</td>
<td>0.036</td>
<td>1.96</td>
</tr>
<tr>
<td>Lung</td>
<td>0.042 ± 0.006</td>
<td>0.055</td>
<td>1.36</td>
</tr>
<tr>
<td>Heart</td>
<td>0.086 ± 0.013</td>
<td>0.086</td>
<td>1.06</td>
</tr>
<tr>
<td>Liver</td>
<td>0.078 ± 0.005</td>
<td>0.780</td>
<td>10.06</td>
</tr>
<tr>
<td>Kidney</td>
<td>0.121 ± 0.012</td>
<td>0.266</td>
<td>2.26</td>
</tr>
<tr>
<td>Stomach</td>
<td>0.071 ± 0.002</td>
<td>0.092</td>
<td>1.36</td>
</tr>
<tr>
<td>Small intestine</td>
<td>0.056 ± 0.012</td>
<td>0.773</td>
<td>13.86</td>
</tr>
<tr>
<td>Pancreas</td>
<td>0.047 ± 0.002</td>
<td>0.038</td>
<td>0.86</td>
</tr>
<tr>
<td>Spleen</td>
<td>0.053 ± 0.017</td>
<td>0.027</td>
<td>0.56</td>
</tr>
<tr>
<td>Muscle</td>
<td>0.059 ± 0.001</td>
<td>7.375</td>
<td>125.06</td>
</tr>
<tr>
<td>Skin</td>
<td>0.089 ± 0.006</td>
<td>3.978</td>
<td>44.96</td>
</tr>
<tr>
<td>Adipose tissue</td>
<td>0.041 ± 0.007</td>
<td>0.718</td>
<td>17.56</td>
</tr>
<tr>
<td>Plasma</td>
<td>1.000</td>
<td>11.200</td>
<td>11.26</td>
</tr>
<tr>
<td>Lymph</td>
<td>0.293 ± 0.058</td>
<td>25.424</td>
<td>231.6</td>
</tr>
</tbody>
</table>

---

* a) Cp (55.26 ± 5.31 μg/ml) was obtained by the constant infusion of GLA at the rate of 0.224 mg/kg/min. b) Results are given as the mean ± S.E. of three rats. The apparent Km value of liver was corrected according to the method of Chen and Gross 23. c) Tissue volume was based on a 250-g rat. d) Determined experimentally from the wet tissue weight by assuming a density of 1.0. e) Reference 34. f) Reference 36. g) Reference 37.
lymph, though the \( K_p \) value of lymph was higher than those of other tissues. This might be related to the anti-inflammatory effect of GLA.\(^2\text{-}^4\) The sum of \( K_p \), \( V_t \) values of skin and muscle was about 80% of \( \sum K_p \cdot V_t \), indicating that almost all GLA is distributed to skin and muscle.

**Discussion**

The plasma concentration versus time curves at each i.v. dose showed the best fit to the two-compartment pharmacokinetic model (Fig. 1B). Subsequently, the relation between \( C_{L_{tot}} \) and plasma concentration at low GLA plasma concentrations (0.1—25 \( \mu \)g/ml) was examined. The relation is expressed as follows:

\[
C_{L_{tot}} = \frac{V \cdot V_{max} \cdot V_t}{C_p \cdot K_m + C_p}
\]  
(3)

where \( C_p \) is plasma concentration of GLA. The elimination rate (\( \tau \)) is given by the following equation:

\[
\tau = \frac{V_{max} \cdot V_t \cdot C_p}{K_m + C_p}
\]  
(4)

As shown in Fig. 5, the \( C_{L_{tot}} \) value was plasma concentration-dependent even at low concentration. Such a dependency might be observed in humans, as the human serum concentrations are \( \sim 0.65 \) and \( \sim 0.8 \) \( \mu \)g/ml after GLZ i.v. (80 mg/man)\(^17\text{,}^18\) and oral (100—182 mg/man)\(^17\text{,}^19\) administrations, respectively. Parke et al.\(^3\text{,}^8\text{,}^39\) reported that after an i.p. dose of \(^3\)H-GLA (25 mg/kg) to rats, all the drug was excreted in the bile as three metabolites (sulfate, monoglucuronide, and diglucuronide conjugates). Previously, we reported that the biliary and urinary excretions of GLA after an i.v. dose (60 mg/kg) in rats were only 0.4 and 0.03% of the dose, respectively.\(^29\) This suggests that almost all GLA is metabolized. Therefore, the dose dependency of GLA disposition may be caused by a saturable metabolism in the clearing organ(s). Since sulfate\(^40\text{,}^41\) and glucuronide\(^42\) conjugations of drugs occur mainly in the liver, GLA may be exclusively metabolized in the liver. In this study, the liver was assumed to be the only eliminating tissue. Accordingly, the apparent \( K_p \) value of liver was corrected according to Eq. 1. As described already, GLA is produced from GLZ after administration of GLZ to humans.\(^17\text{,}^19\) rats,\(^20\text{,}^23\) and rabbits.\(^24\)

In this study, GLA was observed in plasma after an i.v. dose of GLZ (Fig. 3). Previously, we reported that \( \sim 80\% \) of the dose of GLZ is excreted in the bile following i.v. administration of 100 mg/kg to rats and subsequently undergoes enterohepatic recycling.\(^28\) Hattori et al.\(^3\text{,}^5\) reported that GLZ is also hydrolyzed to GLA by human intestinal flora. Such a hydrolysis may occur in rat intestine, but this was not examined in the present study. Parke et al.\(^3\text{,}^8\text{,}^39\) also reported that three GLA-conjugates undergo hydrolysis in the intestine subsequent to their biliary excretion, and then enterohepatic recycling of GLA occurs in rats. The increase of GLA plasma level at 9 h and the sustained level from 9 to 48 h following GLZ i.v. administration (Fig. 3A) may be accounted for by the intestinal reabsorption of GLA produced from GLZ and GLA-conjugates during the enterohepatic recycling of both, because such behavior was not observed in the bile duct-cannulated rats after GLZ dosing, i.e., the GLA plasma level declined with time (Fig. 3B).

The apparent \( V_{du} \) value was small (approximately 2 times the plasma volume)\(^4\text{,}^4\) at each dose (Table 1) and no uptake of GLA into erythrocytes was observed. These results may be caused by the small plasma unbound fraction (0.0076—0.0109) over the plasma concentration range of 2—150 \( \mu \)g/ml studied. Plasma unbound fraction was calculated from the binding parameters reported previously.\(^4\)

It has been reported that GLA plays a major role in the induction of pseudo-aldosteronism through the following mechanisms: (1) GLA binds to kidney aldosterone receptors,\(^13\) (2) GLA potentiates aldosterone action\(^4\) and (3) GLA inhibits aldosterone deactivating enzyme.\(^15\text{,}^16\) Actions (1) and (2) were not observed in the case of GLZ\(^13\text{,}^14\) and GLA is more potent than GLZ as regards action (3).\(^16\) It seems that care may be required in the case of successive administrations of GLA and GLZ to humans, in view of the occurrence in the rat of saturable elimination at low plasma concentrations of GLA, which is the agent mainly responsible for the side-effects.

**Acknowledgement**

This work was supported in part by a Grant-in-Aid from the Shimabara Science Promoting Foundation.

**References and Notes**